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Abstract 
Objective: To evaluate a pilot of a laboratory model for relating pharmacogenetics to clinical decision making. Case Study: This pilot 
was undertaken and evaluated to help determine if a pharmacogenetics laboratory should be included in the core Doctor of 
Pharmacy curriculum. The placement of the laboratory exercise in the curriculum was determined by identifying the point in the 
curriculum where the students had been introduced to the chemistry of deoxyribonucleic acid (DNA) as well as instructed on the 
chemistry of genetic variation. The laboratory included cytochrome P450 2C19 genotyping relative to the *2 variant. Twenty-four 
students served as the pilot group. Students provided buccal swabs as the source of DNA. Students stabilized the samples and were 
then provided instructions related to sample preparation, polymerase chain reaction, and gel electrophoresis. The results were 
reported as images of gels. Students used a reference gel image to compare their results to. Students then applied a dosing algorithm 
to make a “clinical decision” relative to clopidogrel use. Students were offered a post laboratory survey regarding attitudes toward 
the laboratory. Twenty-four students completed the laboratory with genotyping results being provided for 22 students (91.7%). 
Sixteen students were wild-type (*1/*1), while six students were heterozygous (*1/*2). Twenty-three students (96%) completed the 
post laboratory survey. All 23 agreed (6, 26.1%) or strongly agreed (17, 73.9%) that the laboratory “had relevance and value in the 
pharmacy curriculum”. Conclusion: The post pilot study survey exploring a laboratory model for pharmacogenetics related to clinical 
decision making indicated that such a laboratory would be viewed positively by students. This model may be adopted by colleges to 
expand pharmacogenetics education. 
 
 
Introduction 
The importance of teaching pharmacogenetics (PGt) to 
pharmacy students is becoming increasingly evident. 
Pharmacogenetics, relating variation in drug response to a 
specific gene, is gaining acceptance as support data in 
therapeutic decision making.
1-4
 In fact, the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) has 
published dosing guidelines related to specific gene-drug 
pairs.
5,6
 These guidelines are intended to help clinicians apply 
PGt data in therapeutics to maximize drug efficacy and 
minimize or avoid adverse drug reactions.
5
 Currently more 
than 110 drugs have PGt information in their package labeling 
and 17 of these fall within the top 200 most commonly 
prescribed drugs.
7,8
 The list of drugs with PGt information in 
their package labeling will continue to grow as the use of PGt 
data increases in drug development.
9
 As pharmacists have 
been drug-drug interaction experts, the advent of 
pharmacogenetic data will result in pharmacists being gene-
drug interaction experts. In order to be proficient at utilizing 
genetic testing and interpreting and applying 
pharmacogenetics, the pharmacist must have an extensive 
knowledge of the subject. This laboratory exercise is intended 
to provide students with experience in using 
pharmacogenetic data for clinical decision making. 
 
Increasingly, pharmacy students will be required to apply the 
science of PGt to clinical practice.
1-4
 To address this, colleges 
of pharmacy continue to develop their curricula in PGt, with 
approximately 90% of schools including the subject matter in 
their Doctor of Pharmacy curricula as of 2009; an increase 
from 39% as reported in 2005.
10,11
 However, only 2.9% of 
colleges of pharmacy required a PGt laboratory exercise.
10
 
Yet, recent evidence suggests that laboratory exercises in PGt 
are invaluable in teaching students how science “connects” to 
clinical application.
12,13
 
 
Knoell et al.
 
described a genotyping exercise targeting the 
angiotensin converting enzyme gene as part of an elective 
PGt course, with ten student volunteers providing DNA 
samples via buccal swabbing.
12
 The genotyping results were 
integrated into five didactic lectures throughout the course to 
enhance the students understanding of PGt. The expected 
objective of developing the genotyping exercise was to 
“improve pharmacy students’ comprehension of 
pharmacogenomic principles that apply to patient care.”
12
 In 
response to a post exercise/post elective course survey, 
71.9% of responding students agreed or strongly agreed that 
“observing the actual results of a PCR-based genotype 
analysis first-hand in class was very useful for future 
practice.” 
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Also, Krynetskiy et al. incorporated genotyping the n-
acetyltransferase 2 (NAT2) gene into a pharmaceutics course 
offered to students in the second year of their professional 
program.
13
 A total of 150 students participated in two three-
hour laboratory periods and one one-hour discussion period. 
A stated goal of the exercise was to “demonstrate to the 
students the universal character of genetic variability in genes 
coding for drug-metabolizing enzymes and the importance of 
genetic analysis for practical pharmacotherapy.” A survey of 
student attitudes showed that 88.9% of the students agreed 
or strongly agreed that the laboratory exercise helped them 
understand “why pharmacogenetics is so important.”
13
 
 
These PGt laboratory exercises were highly advantageous but 
as yet, no model has been established that can be easily 
integrated into existing curricula. Additionally, to date, no 
model focuses on a gene that directly influences dosing of a 
commonly prescribed medication and requires minimal 
resources in terms of both cost and instructor time. To 
complement the didactic components of PGt education in our 
curriculum, we sought to develop a laboratory exercise that 
directly related the science of PGt to its clinical application. 
We intended to develop an exercise that linked basic science 
to clinical science, where the biochemical information of DNA 
is translated into clinical information which has a clear 
purpose when considering genetic-based dosing guidelines 
used for clinical decision making. Here we present a model 
that meets the above criteria and may be applied to various 
pharmacy curricula. 
 
The Rationale and Objectives of Exploring a PGt Laboratory 
Exercise 
The growing emphasis on the clinical applications of PGt 
provided the rationale for exploring an exercise linking the 
science of genetics to its application in our curricular 
sequence. The objective of our PGt education is to have our 
students understand the scientific basis of genetic variation 
and to be able to interpret and apply that information in 
patient care through personalized medicine. The specific 
objective of the PGt laboratory exercise is to link genetic 
variability to clinical decision making. 
 
The cytochrome P450 2C19 (CYP2C19) gene was selected as 
the target for this exercise due to its clinical relevance and 
established PGt-based dosing guidelines.
14,15
 An excess of one 
million coronary artery stents are placed annually in the 
United States to prevent complications, including death, in 
patients with coronary artery disease.
16,17
 Dual antiplatelet 
therapy is a standard of practice and clopidogrel is a common 
drug used in this setting.
17
 Clopidogrel, a prodrug, requires 
bioactivation to form an active compound, which inhibits 
platelet aggregation by inhibiting adenosine diphosphate 
(ADP) binding to P2Y12 receptors on platelets. This effectively 
decreases platelet aggregation, helping to prevent 
thrombosis. Clopidogrel has been one of the most commonly 
prescribed drugs, with more than 28 million prescriptions 
dispensed in 2011, alone.
8
 While commonly used, the 
pharmacologic response to the drug shows wide interpatient 
variability. This variability has been attributed, in part, to 
genetic variability in the enzyme responsible for the 
bioactivation of clopidogrel, CYP2C19.
14,15
 
 
Numerous single nucleotide polymorphisms (SNPs) have been 
identified for the CYP2C19 gene, resulting in the observed 
interpatient variability associated with response to 
clopidogrel therapy. The most common or wild-type CYP2C19 
gene sequence (designated CYP2C19*1) produces a full-
functioning CYP2C19 enzyme. Variant alleles that result in a 
loss-of-function CYP2C19 enzyme have been identified and 
are designated as *2, *3, *4, *5, *6, *7, and *8. Other variant 
alleles of lesser frequency exist.
14,15
 Indeed, approximately 
30% of Caucasian stent placement patients who take 
clopidogrel may not be optimally benefiting from the drug. 
There is a three-fold increased risk of stent thrombosis 
following placement of the stent(s) in patients carrying at 
least one loss-of-function allele.
18,19
 Of the patients not fully 
benefiting from clopidogrel therapy, approximately 95% carry 
the *2 loss-of-function allele as heterozygotes *1/*2 or 
homozygotes *2/*2.
14,15
 Additionally, the percentage of 
individuals carrying a loss-of-function or reduced function 
allele is greater in other populations (African ~40%; East Asian 
populations ~55%).
14-19
 Genetic-based dosing guidelines for 
the use of clopidogrel in the stent patient population have 
been introduced and are gaining acceptance as a standard of 
care.
14,15,20 
 
Details of the Pilot Pharmacogenetics Laboratory Exercise 
The placement of the model PGt laboratory exercise at a 
specific point in our curriculum was based on the 
examination of our overall PGt content. We chose to include 
the laboratory towards the end of the semester of the first of 
a two-course biochemistry sequence, after the students had 
sufficient instruction on the chemistry of DNA. 
 
Twenty-four students enrolled in the first of two sequential 
biochemistry courses volunteered to participate in the pilot 
testing of the PGt exercise. Each student was provided a 
random four-digit number.
21
 The number was placed on the 
tube containing a swab (Isohelix SK-1; Cell Projects Ltd.; 
Harrietsham, Kent, UK) used for buccal cell sampling. During 
the 11th week of fall semester, three sampling days were 
scheduled, with each limited to eight student volunteers. On 
each sampling day, students reported to the College’s 
common laboratory and received instruction on the process 
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of buccal swabbing as described by the manufacturer. After 
one minute of swabbing, each student placed his or her swab 
into the tube corresponding to the random number he or she 
received. A DNA isolation kit (Isohelix DDK-50; Cell Projects 
Ltd.; Harrietsham, Kent, UK) containing lysis buffer, 
proteinase K, a capture buffer and rehydration buffer was 
used to isolate and stabilize DNA from each buccal sample. 
Each student used single-channel pipettes to add the lysis 
buffer and proteinase K to his or her sample. The stable 
samples were then stored at room temperature until 
preparation for polymerase chain reaction (PCR).  
 
Upon stabilization of their DNA samples, students were 
presented with the process of how their samples would be 
analyzed. A detailed description of sample preparation 
including the use of buffers, specific primers, 
deoxynucleotides, and DNA polymerase was provided. The 
details of the PCR protocol were presented as was the 
process involved with gel electrophoresis. 
 
Alleles for CYP2C19*1 (wild-type) and CYP2C19*2 (loss-of-
function) were genotyped by tetra-primer PCR essentially as 
described by Hersberger et al.
22
 Briefly, approximately 50 ng 
of genomic DNA in 2.0 μL TE buffer (10 mM) Tris, pH 8.0, 1 
mM EDTA was amplified by PCR (cycling conditions: 10 min at 
94˚C; 44 cycles of 30s at 94˚C, 30s at 50˚C, and 60s at 72˚C; 7 
min at 72˚C) using four primers (Ex5U: 
CAGAGCTTGGCATATTGTATC, Ex5L: 
GTAAACACACAACTAGTCAATG, 2mutU:  
ATCATTGATTATTTCCCA, 2wtL: AATTGTTATGGGTTCCC).  
Products were resolved by 2% gel electrophoresis and 
identified as 321-bp (control), 229-bp (CYP2C19*2 allele) and 
127-bp (CYP2C19*1 or wild-type allele). This method was 
employed as it is reproducible as published by Hersberger et 
al.
22
 While more advanced technologies are available it is 
likely the approach utilized here would be more feasible for 
most institutions as standard PCR and electrophoresis are 
commonplace. This method can be used as a “start-up” with 
relatively low expense. 
 
A faculty member and student research assistants (none of 
which were volunteers for the PGt exercise) prepared the 
samples for PCR and performed the PCR and gel 
electrophoresis procedures to obtain genotyping results. 
Figure 1 presents a flow chart of the laboratory model. 
 
Student Interpretation of Pharmacogenetic Testing 
Following the processing of the samples, an image of the 
electrophoresis gel with results for each student was 
provided for analysis. The students, in groups of four to six, 
reported to the common lab or faculty office and were asked 
to identify their individual results by analyzing images of the 
DNA bands in the lane corresponding to the four-digit 
identification number. The students compared their DNA 
band image to those presented by Hersberger et al. in order 
to determine their genotype (Figures 2a and 2b).
22
 Results 
were confirmed using positive control samples derived from 
individuals who were wild-type (*1/*1) or heterozygous 
(*1/*2) for CYP2C19, as determined by commercial 
sequencing (23andMe; Mountain View, CA, USA; Illumina 
BeadChip; Laboratory Corporation of America; Burlington, 
NC, USA). The results of each student’s interpretation, i.e. 
genotype, were recorded next to the four digit number on a 
laboratory form. In the context of the CPIC CYP2C19-
clopidogrel dosing guidelines, each student determined the 
approach they would take regarding the use of clopidogrel or 
an alternative antiplatelet drug for an individual of their 
specific genotype. Here, the students were concerned with 
drug choice only. 
 
Seeking Student Opinions Regarding the Laboratory Exercise 
After this exercise was completed, students were offered, by 
email, a six-question survey to gather their opinions on the 
laboratory experience relative to biochemistry, PGt, and the 
pharmacy curriculum (Figure 1). The survey questions were 
formulated by the faculty piloting the laboratory exercise. 
 
PGt and the Institutional Review Board 
The Ohio Northern University Institutional Review Board (IRB) 
exempted the laboratory exercise pilot study from review as 
the PGt sampling procedure was done with safeguards 
ensuring volunteer anonymity and as the results were not 
associated with an identifiable volunteer. 
 
Yield of PGt Testing Results 
Twenty-four students originally volunteered for the 
genotyping exercise. One student withdrew prior to the 
exercise and was replaced by another student. The students 
would be considered a population of North American 
Caucasians. Of the 24 students who participated, 19 had 
genotype results available to them. Results for five students 
were not provided as technical difficulties prevented analysis 
of the results. Samples from the five students that could not 
be analyzed originally were processed a second time. This 
yielded results for three more students. Of the 22 students 
that were able to interpret their genotype, 16 (72.7%) were 
wild-type (wt/wt;*1/*1) and 6 (27.3%) were heterozygous 
(wt/*2; *1/*2). Our genotyping data provided confirmation of 
the reproducibility of the method of Hersberger et al. (Figure 
2b) and indicated the buccal swab sampling method can be 
employed in the classroom as it would be in the clinical 
setting.
22
 However, it is likely that, while instructed on proper 
collection, some buccal samples did not contain enough DNA 
for amplification. This has been noted previously and it 
Case Study EDUCATION 
 
http://z.umn.edu/INNOVATIONS                      2013, Vol. 4, No. 2, Article 112                          INNOVATIONS in pharmacy   4 
 
should be expected that some samples will not contain 
enough DNA due to poor sampling technique.
23
   With 
discussion of the CPIC guidelines (Figure 3), the six students 
with the heterozygous (*1/*2) genotype concluded that 
antiplatelet therapy with a drug other than clopidogrel would 
be appropriate for a stent placement patient with their 
genotype, whereas students with the wild-type (*1/*1) 
genotype concluded clopidogrel was a valid therapeutic 
option for antiplatelet therapy in stent placement patients 
with this genotype. 
 
Student Opinions of the PGt Laboratory Exercise 
Twenty-three of the 24 students (95.8%) completed the post 
exercise survey. Overall, the exercise was viewed positively as 
indicated by the responses (Table 1). Across all questions, 
relative to the scale of 1=strongly disagree, 2=disagree, 
3=neither agree nor disagree, 4=agree, and 5=strongly agree, 
the mean value was 4.56 + 0.5. Seventeen of the 23 students 
(73.9%) strongly agreed that “the genotyping exercise has 
relevance and value in the pharmacy curriculum.” There was 
not one negative (strongly disagree or disagree) response to 
any question. Two neutral (neither agree nor disagree) 
responses were noted regarding the exercise and 
understanding the concept of a prodrug.  One student 
expressed that they neither agreed nor disagreed that the 
exercise provided a rationale for performing genotyping 
(Table 1). 
 
Placement of the PGt Laboratory Exercise in the Curriculum 
We examined our curriculum to identify a specific point 
where we thought the laboratory exercise would best fit. As a 
“zero-six” program, PGt education at the Raabe College of 
Pharmacy at Ohio Northern University spans six years. In the 
fall of their first year, students are introduced to PGt in the 
introductory biology course, where they search genomic data 
using the Ensembl genome browser to explore cytochrome 
P450 2C9 (CYP2C9) and warfarin dosing.
24
 In the subsequent 
spring, students learn more about PGt in the broader context 
of personalized medicine during the “Profession of 
Pharmacy” course.  Here, a video of a Plavix® (clopidogrel) 
television commercial in which a statement about genetic 
testing is made is shown to the students and discussed.  In 
the second year, students learn about the human genome 
project and DNA sequencing in the “Applied Science of 
Pharmacy” course.  The students are introduced to 
polymerase chain reaction and gel electrophoresis.  In the 
third year, students learn the “chemistry of DNA” in a two-
course biochemistry sequence.  The “Biomedical Science 
(BMS)” module teaches PGt related to pharmacokinetics and 
pharmacodynamics in the early spring of the fourth year.  
Starting that semester, following the BMS module and 
throughout the fifth year, students learn about specific drug-
gene interactions as they progress through a sequence of five 
“therapeutics” modules.  The topics of PGt and personalized 
medicine are updated in late spring semester of the fifth year, 
in a “capstone” course, prior to the students starting their 
advanced pharmacy practice experiences (APPEs).  Some 
students take the opportunity to participate in an elective 
APPE focusing on PGt in the sixth year.  In total the students 
receive over 30 hours of required PGt and related instruction.  
 
We had considered the cardiovascular therapeutic module as 
a potential “home” for the exercise, however, the module is 
presented considerably later in the curriculum relative to the 
basic science “chemistry of DNA” subject matter. Therefore, 
we chose to include the exercise in the first biochemistry 
course. In this course, the mechanism of DNA replication is 
covered in detail.  Deoxyribonucleic acid replication fidelity 
and processivity are explained, and carefully differentiated.  
The topics of fidelity and processivity introduce a more 
detailed discussion of DNA errors and repair mechanisms.  
The types of DNA errors that exist are introduced as well as 
their relative rate of occurrence.  DNA repair mechanisms are 
then covered including nucleotide and base excision repair, 
direct repair, mismatch repair and transpositional 
recombination. During class discussion, students are 
encouraged to consider the meaning of loss of function of 
proteins based on DNA variation and to think of examples, 
after which the instructor guides them to consider PGt 
examples. Following the presentation of content related to 
replication of both DNA and ribonucleic acid (RNA), a didactic 
series on transcription and translation begins. A list of the 
general functions of various transcription factors is provided. 
Following the presentation of the transcription factors a 
summary is presented of methods for gene expression 
regulation. This includes regulation at the chromatin level, 
transcription initiation, and finally transcription beyond the 
basal level. In addition to these general genetic processing 
topics, specific examples are provided. For example, the 
importance of variation in DNA resulting in an altered amino 
acid sequence is discussed in reference to warfarin dosing. 
This example is provided to emphasize the effects that a SNP 
can have on an amino acid sequence and subsequently on 
protein function. It is at this point we chose to include the 
PGt laboratory exercise. 
 
Similar to colleges/schools of pharmacy that offer a “2-4” 
program, the majority of the basic science courses are 
offered in the first two years of our “0-6” program and 
integration of the pharmacogenetics laboratory into the 
curriculum was considered in light of the students having a 
sufficient basic science foundation. Other colleges may 
choose a different point in their curriculum to introduce a PGt 
laboratory exercise. The current laboratory model can be 
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utilized in any number of places in a given curriculum, once 
the students have a basic science knowledge base.  
 
The Gene-Drug Pair 
A clear benefit of this model is the use of published genotype-
based dosing guidelines related to one of the most commonly 
prescribed drugs.
14,15
 In fact, in 2011 clopidogrel was the 
seventh most commonly prescribed drug.
8
 When considering 
this exercise, we chose to have the students engage in the 
collection of a DNA sample, as may typically be done in the 
clinical setting, and to perform the process of stabilizing the 
DNA. We chose a gene-drug pair that has clear clinical 
relevance, here being CYP2C19 genotyping relative to 
clopidogrel. The indication-specific use of CYP2C19 
genotyping in stent placement patients has recently been 
discussed and has been made clear to our students.
20
 As 
approximately 30% of individuals carry a loss-of-function 
CYP2C19 variant, and as 95% of those with a variant have the 
*2 form, the choice of specifically testing for CYP2C19*2 was 
made.  In this exercise, 27.3% (6 of 22) individuals were 
heterozygous *1/*2 individuals, similar to the frequency 
observed in a similar Caucasian population.
15
 As students 
were in groups of four to six when reviewing the gel images, 
there was some discussion between them about how to 
interpret the bands (not specific to an individual as the data 
were randomly coded with a four-digit number), which likely 
influenced some genotype determinations. Similarly, once 
some of the students discussed the use of the algorithm to 
determine the appropriate antiplatelet drug, others seemed 
to make their decision more rapidly, likely because they had 
been provided with “instructions” from their student 
colleagues’ discussions in the group setting. The “call” of the 
genotype was not a specific “test” question noted as 
“correct” or “incorrect”. 
 
Importantly, regardless of the number of students 
participating, anonymity must be maintained. IRB approval 
was based on the design including anonymity. Certainly, a 
student could opt out of providing their DNA.  Here, a student 
making this decision could be provided with anonymous data 
to use.  However, the exercise may have more “appeal” to 
some students based on the use of their own DNA. 
 
In the current exercise, the students utilized their own DNA 
results to make a “clinical decision” based on their genotype. 
The students were informed that the data provided through 
this exercise came from a non-Clinical Laboratory 
Improvement Amendment (CLIA) certified laboratory and was 
not to be utilized in a true clinical setting. In fact, although 
not required by the IRB and to address some concerns of 
educational DNA testing, we had the students sign a 
statement that they understood this point.
25
 Additionally, we 
discussed that the data they evaluated was not presented in 
the format they would see in the clinical setting. i.e., they 
would refer to a laboratory report for data and not be 
interpreting images of gels. 
 
Connecting the science of DNA with clinical application of PGt 
is a way to raise the expectations of pharmacy students 
regarding personalized medicine and this model provides a 
method to accomplish this.
26
 A clear benefit of this model is 
the use of published genotype-based dosing guidelines 
related to one of the most commonly prescribed drugs.
14,15
 In 
fact and as stated earlier, in 2011 clopidogrel was the seventh 
most commonly prescribed drug.
8
  
 
As eventual pharmacotherapy experts, it is important to have 
the students see the origin of genotyping data and 
understand that they, as pharmacists, will be expected to 
know when to recommend PGt testing and importantly 
interpret and apply PGt testing results. This laboratory 
exercise provided the students with an example of generation 
of DNA data. The exercise provided the students with 
experience in interpreting data and applying the data through 
use of genetic-based dosing guidelines as applied in 
pharmacy practice.
4, 6, 14
  
 
PGt Laboratory Time Commitments 
The student volunteers involved in this exercise spent a total 
of 50 minutes involved in sample collection, stabilization, and 
instruction on sample handling, processing and reporting. 
Thirty-five minutes were used with the initial meeting for the 
swabbing, DNA stabilization, and presentation of the PCR and 
gel electrophoresis procedures and 15 minutes were used 
later to view the data and interpret the results. The time 
commitment for the faculty member was 8.4 hours, including 
the time with the students, performing sample preparation, 
PCR and gel electrophoresis. The student lab assistants spent 
approximately five hours working with the faculty member 
processing the samples. The time increased to approximately 
7.5 hours for the student lab assistants as they ran the repeat 
analysis of samples that were not able to be evaluated after 
the first attempt. The turn-around time on the samples, from 
collection to reporting of results was six days.  At our 
institution, with typical class sizes of 165 students, expanding 
this exercise to the entire class would potentially increase 
faculty time commitment to 13 to 14 hours per semester. The 
laboratory assistant’s time would increase also, however, 
genotyping, for other reasons is part of the typical daily 
workload and the additional work would not significantly 
increase their time commitment. The turn-around of samples 
will necessarily take longer due to the larger volume of 
samples.  With larger class sizes, it may be efficient to have 
the students perform the buccal swabbing only and forgo the 
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DNA stabilization step using the pipettes.  In this case, the 
sample processing, PCR conditions and gel electrophoresis 
technique could be presented after the students complete 
the buccal sampling. This would significantly decrease faculty 
time commitment as the material would be presented once 
to the entire class as opposed to multiple times to small 
groups. 
 
PGt Laboratory Costs 
The cost associated with this pilot exercise includes supplies 
and reagents for sample collection, preparation, PCR reagents 
and supplies, as well as supplies for gel electrophoresis. The 
total cost per sample (per student) was approximately $6. 
This cost was not considered to be prohibitive. With class 
sizes of approximately 165 students, an annual budget for the 
lab of $990 would be expected. Regardless, the 
instrumentation and equipment for the genotyping exercise 
is relatively minimal, including a vortex mixer, heat block, 
micro-centrifuge, thermocycler, and gel electrophoresis 
equipment, with a total cost of $8,000 to $10,000. Many 
institutions will have the laboratory 
equipment/instrumentation available as PCR and gel 
electrophoresis are common techniques.  
 
Next Steps 
Student response to the genotyping exercise pilot indicated 
the importance of the exercise. The results will help us to 
move forward with implementing the exercise for the entire 
biochemistry class in the subsequent academic year.  At that 
time, with the entire class interpreting their individual results, 
we will use a “real time” capture technology to record the 
frequency of individuals who are wild-type (*1/*1), 
heterozygotic or homozygotic for the *2 allele.  Here, 
students will compare the class aggregate data with 
published genotype frequencies in a similar population.  The 
students understanding of the use of genetic data in the 
context of clinical decision making will be tested on two 
occasions, including a multiple choice exam and a 
comprehensive final exam with various question formats. 
 
Additionally, the laboratory exercise will be considered 
relative to pharmacogenomics (PGx; encompassing PGt) 
competencies for pharmacists, which are currently being 
developed.
27
 Pharmacy student education relative to PGx 
must be considered in the context of the practice of 
pharmacy where pharmacists will be viewed as the gene-drug 
interaction experts. Colleges of pharmacy must work to make 
this an expectation of the pharmacy student.   
 
Conclusions 
This approach can be adopted by other colleges of pharmacy 
with the expectation of students: 1) relating biochemistry and 
pharmacogenetics to clinical application, 2) understanding 
the basic process of genetic sampling and genotyping, 3) 
realizing the rationale for performing genotyping, and 4) 
recognizing the relevance and value of the laboratory 
exercise in their pharmacy education. Key to this approach is 
tying in the science with the use of clinical dosing guidelines. 
As students progress through a curriculum, the use of 
pharmacogenetic information, whether it is based on 
population allele frequencies or individual genotype, can be 
pointed to as a clear example of the clinical application of 
basic science. When a gene-drug pair is presented in the 
context of genetic testing, the student will relate the 
laboratory exercise to clinical application. This shows the 
student the direct connection of the science with clinical 
decision making. This model is unique in that the students 
learn skills that are translational to practice and can be 
applied clinically; obtaining genomic DNA through a buccal 
swab and interpreting PGt results relative to specific dosing 
guidelines.  
 
The laboratory model proved to be successful and has 
resulted in adoption of the model for subsequent 
biochemistry courses as a required exercise. The model was 
easily implemented and both time and dollar investments 
were considered to be reasonable.  
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Table 1. Post pilot genotyping exercise survey results.  (N=23) 
 
 
Question 
Strongly 
Disagree 
(1)  
Disagree  
(2) 
Neither 
Agree/Disagree 
(3) 
Agree (4) 
Strongly 
Agree  
(5) 
Mean + SD 
The genotyping 
exercise related 
biochemistry and 
pharmacogenetics to 
clinical application. 
0 0 0 
7 
(30.4%) 
16 
(69.6%) 
4.70 
+ 
0.47 
The genotyping 
exercise helped me 
understand the 
concepts of genetic 
variation and 
polymorphisms. 
0 0 0 
15 
(65.2%) 
8 
(34.8%) 
4.35 
+ 
0.49 
The genotyping 
exercise helped me 
understand the 
concept of a prodrug 
and metabolism to an 
active drug. 
0 0 
2 
(8.7%) 
10 
(43.5%) 
11 
(47.8%) 
4.39 
+ 
0.66 
The exercise helped 
me understand the 
basic process of how 
genetic sampling and 
genotyping is 
performed. 
0 0 0 
7 
(30.4%) 
16 
(69.6%) 
4.70 
+ 
0.47 
The exercise provided 
me with a rationale 
for performing 
genotyping. 
0 0 
1 
(4.3%) 
14 
(60.9%) 
8 
(34.8%) 
4.30 
+ 
0.56 
The genotyping 
exercise has relevance 
and value in the 
pharmacy curriculum. 
0 0 0 
6 
(26.1%) 
17 
(73.9%) 
4.74 
+ 
0.44 
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Figure 1. Flow chart describing the pharmacogenetic laboratory pilot. 
 
Students Report to Common Lab: 
-provided with a 4-digit random 
number. 
-swab cheek for 1 minute. 
-place swab in tube with 
corresponding 4-digit number. 
-stabilize DNA 
- receive detailed description of DNA 
preparation, PCR protocol, and gel 
electrophoresis method. 
 
-35 minutes 
Students 
Volunteer 
n = 24 
Six day period for sample analysis and reporting 
Faculty and laboratory 
assistants perform DNA 
isolation, PCR, and gel 
electrophoresis. Produce 
image of gel (genotyping 
results). 
 -repeat analysis 
 for samples not 
 providing results. 
 
-5 to 7.5 hours 
Students Report to Common Lab: 
-provided with image of gel 
 -evaluate DNA bands in lane matching 4-digit number 
 -report genotype 
 -use CPIC guidelines to make “clinical decision” 
-15 minutes 
 
Survey emailed to students 
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Figure 2a. Example image of gel electrophoresis results. 
 
 
Figure 2a. Representative image of gel electrophoresis with an example four-digit random number  
as assigned to each volunteer. The genotype of each volunteer is noted at the bottom of each lane.  
*1/*1 = extensive metabolizer, *1/*2 = intermediate metabolizer, *2/*2 = poor metabolizer.  
The results here, presented as examples, were not related to students in the described pilot exercise. 
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Figure 2b. Reference image of gel electrophoresis results as presented by Hersberger et al.
22 
 
 
Figure 2b. Reference image of gel electrophoresis results for CYP2C19 genotyping.  
Wt = normal function allele (*1), *2 = loss-of-function allele, Wt/*2 = heterozygous (*1/*2).  
Reprinted by permission from the American Association for Clinical Chemistry: [Clinical Chemistry]  
Hersberger M, Marti-Jaun J, Rentsch K, Hänseler E. Two single-tube tetra-primer assays to detect 
the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem. 47:772-774,  copyright 2001.  
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Figure 3. CPIC CYP2C19-clopidogrel dosing algorithm. 
 
Figure 3. Algorithm for suggested clinical actions based on CYP2C19 genotype in patients with acute coronary syndromes 
initiating antiplatelet therapy. ACS, acute coronary syndrome; EM, extensive metabolizer; IM, intermediate metabolizer; 
PCI, percutaneous coronary intervention; PM, poor metabolizer; UM, ultrarapid metabolizer. Other rare CYP2C19 
genotypes exist apart from those illustrated.  Higher-dose clopidogrel has not been adequately studied at the time of this 
writing but may improve platelet function in a subset of IMs and PMs.  Note that prasugrel is recommended only when its 
use is not clinically contraindicated. Reprinted by permission from Macmillan Publishers Ltd: [Clinical Pharmacology and 
Therapeutics] Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for 
cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 90(2):328-332, copyright 2011. 
